Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Fourcade

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinics in Dermatology|April 24, 2013
Strategies to reverse melanoma-induced T-cell dysfunctionJulien Fourcade, Hassane M Zarour
Journal of Immunology (Baltimore, Md. : 1950)|December 7, 2010
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1Pavol Kudela, Zhaojun Sun, Julien Fourcade, et al.
Cancer Research|February 28, 2015
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T CellsZhaojun Sun, Julien Fourcade, Ornella Pagliano, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoireJulien Fourcade, Zhaojun Sun, Pavol Kudela, et al.
The Journal of Experimental Medicine|September 8, 2010
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patientsJulien Fourcade, Zhaojun Sun, Mourad Benallaoua, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patientsPavol Kudela, Bratislav Janjic, Julien Fourcade, et al.
Cancer Research|December 30, 2011
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1Julien Fourcade, Zhaojun Sun, Ornella Pagliano, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 10, 2008
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patientsJulien Fourcade, Pavol Kudela, Pedro A Andrade Filho, et al.
The Journal of Clinical Investigation|April 14, 2015
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patientsJoe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2009
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patientsJulien Fourcade, Pavol Kudela, Zhaojun Sun, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinics in Dermatology|April 24, 2013
Strategies to reverse melanoma-induced T-cell dysfunctionJulien Fourcade, Hassane M Zarour
Journal of Immunology (Baltimore, Md. : 1950)|December 7, 2010
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1Pavol Kudela, Zhaojun Sun, Julien Fourcade, et al.
Cancer Research|February 28, 2015
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T CellsZhaojun Sun, Julien Fourcade, Ornella Pagliano, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoireJulien Fourcade, Zhaojun Sun, Pavol Kudela, et al.
The Journal of Experimental Medicine|September 8, 2010
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patientsJulien Fourcade, Zhaojun Sun, Mourad Benallaoua, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patientsPavol Kudela, Bratislav Janjic, Julien Fourcade, et al.
Cancer Research|December 30, 2011
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1Julien Fourcade, Zhaojun Sun, Ornella Pagliano, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 10, 2008
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patientsJulien Fourcade, Pavol Kudela, Pedro A Andrade Filho, et al.
The Journal of Clinical Investigation|April 14, 2015
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patientsJoe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2009
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patientsJulien Fourcade, Pavol Kudela, Zhaojun Sun, et al.
Pageof 2